세계의 전이성 암 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료 유형별, 암 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Metastatic Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Therapy Type, By Type of Cancer, By End-User, By Region & Competition, 2020-2030F
전이성 암 치료제 세계 시장 규모는 2024년 787억 5,000만 달러로 평가되었고, 2030년까지 7.35%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 괄목할만한 성장이 예상됩니다.
전이성 암 치료제 세계 시장은 제약 산업에서 중요하고 빠르게 발전하고 있는 분야로, 원발 부위를 넘어 전이된 암에 대한 첨단 치료법 개발에 전념하고 있습니다. 이러한 약물은 종양의 진행을 늦추고, 증상을 관리하며, 환자의 삶의 질을 향상시키기 위해 고안된 약물입니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
787억 5,000만 달러 |
| 시장 규모 : 2030년 |
1,208억 달러 |
| CAGR : 2025-2030년 |
7.35% |
| 급성장 부문 |
유방암 |
| 최대 시장 |
북미 |
상당한 진전에도 불구하고, 치료 비용의 상승과 특정 암종에 대한 치료의 한계 등 시장은 여전히 중요한 문제에 직면해 있습니다. 예를 들어, 췌장암은 여전히 높은 치사율을 보이고 있으며, 포르피리녹스와 같은 표준 치료의 효과는 제한적입니다.
그러나 암 발병률 증가, 치료법의 지속적인 기술 혁신, 전략적 업계 제휴 등이 원동력이 되어 강력한 성장 전망을 남기고 있습니다. 지속적인 시장 확대를 위해서는 특히 치료가 어려운 암의 경우, 치료 비용의 적정성 및 유효성 문제를 해결하는 것이 필수적입니다.
주요 시장 성장 촉진요인
전이성 암 유병률 증가
주요 시장 이슈
의약품 개발 비용과 시간적 제약
주요 시장 동향
면역요법의 장점
연구진은 반응률을 높이고 내성을 극복하기 위해 면역요법과 표적치료, 화학요법 등 다른 치료법과의 병용을 모색하고 있습니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 전이성 암 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 치료 유형별(화학요법, 면역치료, 호르몬요법, 표적치료, 기타)
- 암 유형별(유방암, 폐암, 전립선암, 흑색종, 대장암, 기타)
- 최종사용자별(병원 및 진료소, 외래 센터, 기타)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 전이성 암 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 전이성 암 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 전이성 암 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 전이성 암 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 전이성 암 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 전이성 암 치료제 시장 : SWOT 분석
제14장 경쟁 구도
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- AstraZeneca Plc
- Novartis AG
- Eli Lilly & Co.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Amgen Inc.
- Sanofi SA.
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
Global Metastatic Cancer Drugs Market was valued at USD 78.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.35% through 2030. The Global Metastatic Cancer Drugs Market is a vital and rapidly evolving sector within the pharmaceutical industry, dedicated to developing advanced therapies for cancers that have spread beyond their original site. These drugs are designed to slow tumor progression, manage symptoms, and enhance patients' quality of life.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 78.75 Billion |
| Market Size 2030 | USD 120.80 Billion |
| CAGR 2025-2030 | 7.35% |
| Fastest Growing Segment | Breast Cancer |
| Largest Market | North America |
Despite significant advancements, the market continues to face key challenges, including high treatment costs and limited progress in certain cancer types. For instance, pancreatic cancer remains highly lethal, with standard treatments such as Folfirinox offering only limited efficacy.
However, strong growth prospects remain, driven by rising cancer prevalence, continuous innovations in therapy, and strategic industry collaborations. To ensure sustained market expansion, addressing issues related to treatment affordability and effectiveness, particularly for hard-to-treat cancers, will be essential.
Key Market Drivers
The Rising Prevalence Of Metastatic Cancer
The rising prevalence of metastatic cancer is a significant market driver in the Global Metastatic Cancer Drugs Market. This phenomenon is multifaceted and can be attributed to several interconnected reasons, all of which have a substantial impact on the demand for metastatic cancer drugs.
One of the primary factors contributing to the increasing prevalence of metastatic cancer is the global demographic shift toward an aging population. As people age, their risk of developing cancer, including metastatic cancer, increases. This is because the incidence of cancer tends to rise with age, and as a result, there is a growing pool of potential patients requiring cancer treatment. Modern lifestyle choices have also played a pivotal role in the rising incidence of metastatic cancer. Factors such as poor diet, lack of physical activity, smoking, and excessive alcohol consumption are known risk factors for various types of cancer, including those that can metastasize. As these unhealthy habits become more prevalent in society, the occurrence of cancer cases, including metastatic ones, continues to rise. Environmental factors, including exposure to carcinogens and pollutants, have been linked to an increased risk of cancer. Industrialization, urbanization, and the expansion of certain industries have led to greater exposure to harmful substances, contributing to the incidence of metastatic cancer in some regions.
Key Market Challenges
Drug Development Costs and Time Constraints
Developing metastatic cancer drugs is a resource-intensive and time-consuming process. Clinical trials alone can take several years and cost billions of dollars. The need for extensive research, preclinical studies, regulatory approvals, and post-marketing surveillance significantly adds to the expenses and timelines. Additionally, the high attrition rate of experimental drugs during clinical trials further compounds the costs and extends development timelines.
Key Market Trends
Immunotherapy Dominance
Immunotherapy has emerged as a dominant trend in the treatment of metastatic cancer due to its remarkable efficacy and potential for long-lasting responses. Key factors contributing to this trend include:
Immunotherapies, such as immune checkpoint inhibitors (e.g., PD-1 and PD-L1 inhibitors) and CAR-T cell therapies, have demonstrated unprecedented success in treating certain metastatic cancers. Patients who had limited treatment options in the past are now experiencing durable responses and improved survival rates. Immunotherapy can be personalized based on a patient's immune profile and tumor characteristics. This tailoring of treatment enhances its effectiveness and minimizes adverse effects, making it an attractive option.
Researchers are exploring combinations of immunotherapies with other treatment modalities, such as targeted therapies and chemotherapy, to enhance response rates and overcome resistance.
Key Market Players
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- AstraZeneca Plc
- Novartis AG
- Eli Lilly & Co.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Amgen Inc.
- Sanofi SA
Report Scope:
In this report, the Global Metastatic Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Metastatic Cancer Drugs Market, By Therapy Type:
- Chemotherapy
- Immunotherapy
- Hormone Therapy
- Targeted Therapy
- Others
Metastatic Cancer Drugs Market, By Type of Cancer:
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Melanoma
- Colorectal Cancer
- Others
Metastatic Cancer Drugs Market, By End User:
- Hospital & Clinics
- Ambulatory Centers
- Others
Metastatic Cancer Drugs Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Cancer Drugs Market.
Available Customizations:
Global Metastatic Cancer Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Metastatic Cancer Drugs Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Therapy Type (Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Others)
- 5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Colorectal Cancer, Others)
- 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Centers, Other)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Metastatic Cancer Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Therapy Type
- 6.2.2. By Type of Cancer
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Metastatic Cancer Drugs Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Therapy Type
- 6.3.1.2.2. By Type of Cancer
- 6.3.1.2.3. By End User
- 6.3.2. Canada Metastatic Cancer Drugs Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Therapy Type
- 6.3.2.2.2. By Type of Cancer
- 6.3.2.2.3. By End User
- 6.3.3. Mexico Metastatic Cancer Drugs Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Therapy Type
- 6.3.3.2.2. By Type of Cancer
- 6.3.3.2.3. By End User
7. Europe Metastatic Cancer Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Therapy Type
- 7.2.2. By Type of Cancer
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Metastatic Cancer Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Therapy Type
- 7.3.1.2.2. By Type of Cancer
- 7.3.1.2.3. By End User
- 7.3.2. United Kingdom Metastatic Cancer Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Therapy Type
- 7.3.2.2.2. By Type of Cancer
- 7.3.2.2.3. By End User
- 7.3.3. Italy Metastatic Cancer Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Therapy Type
- 7.3.3.2.2. By Type of Cancer
- 7.3.3.2.3. By End User
- 7.3.4. France Metastatic Cancer Drugs Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Therapy Type
- 7.3.4.2.2. By Type of Cancer
- 7.3.4.2.3. By End User
- 7.3.5. Spain Metastatic Cancer Drugs Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Therapy Type
- 7.3.5.2.2. By Type of Cancer
- 7.3.5.2.3. By End User
8. Asia-Pacific Metastatic Cancer Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Therapy Type
- 8.2.2. By Type of Cancer
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Metastatic Cancer Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Therapy Type
- 8.3.1.2.2. By Type of Cancer
- 8.3.1.2.3. By End User
- 8.3.2. India Metastatic Cancer Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Therapy Type
- 8.3.2.2.2. By Type of Cancer
- 8.3.2.2.3. By End User
- 8.3.3. Japan Metastatic Cancer Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Therapy Type
- 8.3.3.2.2. By Type of Cancer
- 8.3.3.2.3. By End User
- 8.3.4. South Korea Metastatic Cancer Drugs Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Therapy Type
- 8.3.4.2.2. By Type of Cancer
- 8.3.4.2.3. By End User
- 8.3.5. Australia Metastatic Cancer Drugs Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Therapy Type
- 8.3.5.2.2. By Type of Cancer
- 8.3.5.2.3. By End User
9. South America Metastatic Cancer Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Therapy Type
- 9.2.2. By Type of Cancer
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Metastatic Cancer Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Therapy Type
- 9.3.1.2.2. By Type of Cancer
- 9.3.1.2.3. By End User
- 9.3.2. Argentina Metastatic Cancer Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Therapy Type
- 9.3.2.2.2. By Type of Cancer
- 9.3.2.2.3. By End User
- 9.3.3. Colombia Metastatic Cancer Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Therapy Type
- 9.3.3.2.2. By Type of Cancer
- 9.3.3.2.3. By End User
10. Middle East and Africa Metastatic Cancer Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Therapy Type
- 10.2.2. By Type of Cancer
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Metastatic Cancer Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Therapy Type
- 10.3.1.2.2. By Type of Cancer
- 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Metastatic Cancer Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Therapy Type
- 10.3.2.2.2. By Type of Cancer
- 10.3.2.2.3. By End User
- 10.3.3. UAE Metastatic Cancer Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Therapy Type
- 10.3.3.2.2. By Type of Cancer
- 10.3.3.2.3. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Metastatic Cancer Drugs Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Bristol-Myers Squibb Company
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. Merck & Co., Inc.
- 14.3. AstraZeneca Plc
- 14.4. Novartis AG
- 14.5. Eli Lilly & Co.
- 14.6. Pfizer Inc.
- 14.7. F. Hoffmann-La Roche Ltd.
- 14.8. Johnson & Johnson
- 14.9. Amgen Inc.
- 14.10.Sanofi SA.
15. Strategic Recommendations
16. About Us & Disclaimer
